 Corey Lyon
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physicians, Family | 2 | 2022 | 201 | 1.170 |
Why?
| | Anticoagulants | 2 | 2025 | 664 | 1.070 |
Why?
| | Osteoarthritis, Knee | 2 | 2018 | 254 | 0.920 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2024 | 2531 | 0.890 |
Why?
| | Hypertension | 4 | 2022 | 1295 | 0.860 |
Why?
| | Glucocorticoids | 3 | 2018 | 594 | 0.830 |
Why?
| | Venous Thrombosis | 1 | 2025 | 190 | 0.820 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2020 | 257 | 0.810 |
Why?
| | Medical Staff | 2 | 2022 | 16 | 0.810 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 85 | 0.790 |
Why?
| | Papillomavirus Infections | 2 | 2020 | 325 | 0.760 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 103 | 0.760 |
Why?
| | Metformin | 2 | 2023 | 331 | 0.730 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 1040 | 0.730 |
Why?
| | Sphygmomanometers | 1 | 2021 | 9 | 0.720 |
Why?
| | Insulin, Isophane | 1 | 2021 | 21 | 0.710 |
Why?
| | Automation | 1 | 2021 | 95 | 0.700 |
Why?
| | Humans | 56 | 2025 | 137585 | 0.690 |
Why?
| | Insulin Glargine | 1 | 2021 | 84 | 0.680 |
Why?
| | Employment | 1 | 2022 | 178 | 0.670 |
Why?
| | Prediabetic State | 1 | 2023 | 253 | 0.660 |
Why?
| | Preventive Health Services | 1 | 2022 | 148 | 0.660 |
Why?
| | Analgesia, Obstetrical | 1 | 2020 | 20 | 0.660 |
Why?
| | Blood Pressure Determination | 1 | 2021 | 157 | 0.650 |
Why?
| | Ganglion Cysts | 1 | 2020 | 9 | 0.650 |
Why?
| | Analgesia, Epidural | 1 | 2020 | 33 | 0.650 |
Why?
| | Aspirin | 2 | 2020 | 387 | 0.640 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 447 | 0.640 |
Why?
| | Smoking Cessation | 1 | 2024 | 442 | 0.640 |
Why?
| | Post-Concussion Syndrome | 1 | 2023 | 175 | 0.640 |
Why?
| | Papillomaviridae | 1 | 2020 | 125 | 0.630 |
Why?
| | Anti-Bacterial Agents | 2 | 2021 | 1809 | 0.620 |
Why?
| | C-Reactive Protein | 2 | 2021 | 410 | 0.620 |
Why?
| | Wrist | 1 | 2020 | 54 | 0.620 |
Why?
| | Spironolactone | 1 | 2019 | 36 | 0.610 |
Why?
| | Diuretics | 1 | 2019 | 74 | 0.610 |
Why?
| | Memory | 1 | 2021 | 248 | 0.600 |
Why?
| | Probiotics | 1 | 2019 | 54 | 0.600 |
Why?
| | Ketorolac | 1 | 2019 | 20 | 0.600 |
Why?
| | Glucosamine | 1 | 2018 | 13 | 0.600 |
Why?
| | Erythromycin | 1 | 2018 | 25 | 0.590 |
Why?
| | Rh-Hr Blood-Group System | 1 | 2018 | 12 | 0.580 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 350 | 0.580 |
Why?
| | Glycemic Index | 1 | 2018 | 27 | 0.570 |
Why?
| | Viscosupplements | 1 | 2018 | 11 | 0.570 |
Why?
| | Ureteral Calculi | 1 | 2018 | 14 | 0.570 |
Why?
| | Sweating | 1 | 2018 | 40 | 0.560 |
Why?
| | Acute Pain | 1 | 2019 | 50 | 0.560 |
Why?
| | Musculoskeletal System | 1 | 2018 | 48 | 0.550 |
Why?
| | Hot Flashes | 1 | 2018 | 87 | 0.530 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 119 | 0.530 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 36 | 0.530 |
Why?
| | Patient Education as Topic | 2 | 2022 | 766 | 0.530 |
Why?
| | Testosterone | 1 | 2021 | 409 | 0.520 |
Why?
| | Labor, Obstetric | 1 | 2017 | 61 | 0.510 |
Why?
| | Warfarin | 1 | 2017 | 154 | 0.510 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 201 | 0.500 |
Why?
| | Hypoglycemia | 1 | 2021 | 445 | 0.500 |
Why?
| | Family Practice | 2 | 2018 | 464 | 0.500 |
Why?
| | Athletic Injuries | 1 | 2023 | 529 | 0.500 |
Why?
| | Telemedicine | 2 | 2022 | 862 | 0.500 |
Why?
| | Melatonin | 1 | 2017 | 150 | 0.490 |
Why?
| | Analgesics | 1 | 2018 | 206 | 0.490 |
Why?
| | Factor Xa Inhibitors | 1 | 2017 | 172 | 0.490 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 106 | 0.490 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2016 | 27 | 0.490 |
Why?
| | Methylprednisolone | 1 | 2016 | 86 | 0.480 |
Why?
| | Job Satisfaction | 1 | 2018 | 218 | 0.480 |
Why?
| | Hyaluronic Acid | 1 | 2018 | 225 | 0.480 |
Why?
| | Practice Guidelines as Topic | 4 | 2020 | 1587 | 0.480 |
Why?
| | Migraine Disorders | 1 | 2017 | 102 | 0.480 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1477 | 0.480 |
Why?
| | Acute Coronary Syndrome | 1 | 2019 | 279 | 0.480 |
Why?
| | Brain Concussion | 1 | 2023 | 574 | 0.460 |
Why?
| | Menopause | 1 | 2018 | 320 | 0.450 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 806 | 0.430 |
Why?
| | Cough | 1 | 2015 | 122 | 0.430 |
Why?
| | Drug Administration Schedule | 3 | 2025 | 786 | 0.420 |
Why?
| | Patient Care Team | 2 | 2018 | 631 | 0.420 |
Why?
| | Exercise Therapy | 1 | 2018 | 443 | 0.410 |
Why?
| | Antioxidants | 1 | 2017 | 584 | 0.410 |
Why?
| | Insulin | 1 | 2024 | 2409 | 0.410 |
Why?
| | Respiratory Tract Diseases | 1 | 2015 | 184 | 0.410 |
Why?
| | Myofascial Pain Syndromes | 2 | 2023 | 12 | 0.400 |
Why?
| | Acupuncture Therapy | 2 | 2023 | 21 | 0.400 |
Why?
| | Adrenal Cortex Hormones | 1 | 2017 | 565 | 0.400 |
Why?
| | Mass Screening | 2 | 2022 | 1287 | 0.400 |
Why?
| | Atrial Fibrillation | 1 | 2017 | 388 | 0.390 |
Why?
| | Virus Diseases | 1 | 2015 | 212 | 0.390 |
Why?
| | Behavior Therapy | 3 | 2023 | 264 | 0.380 |
Why?
| | Health Promotion | 1 | 2018 | 741 | 0.360 |
Why?
| | Low Back Pain | 2 | 2023 | 108 | 0.360 |
Why?
| | Cardiovascular Diseases | 2 | 2020 | 2111 | 0.340 |
Why?
| | Pain Measurement | 4 | 2023 | 521 | 0.330 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7635 | 0.320 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2020 | 140 | 0.280 |
Why?
| | Aged | 10 | 2021 | 23961 | 0.280 |
Why?
| | Depression | 1 | 2017 | 1397 | 0.280 |
Why?
| | Organizational Innovation | 2 | 2019 | 140 | 0.270 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 238 | 0.270 |
Why?
| | Female | 16 | 2023 | 73304 | 0.270 |
Why?
| | Abdomen, Acute | 1 | 2006 | 21 | 0.260 |
Why?
| | Pregnancy | 4 | 2022 | 6763 | 0.260 |
Why?
| | Azithromycin | 2 | 2018 | 100 | 0.260 |
Why?
| | Middle Aged | 11 | 2021 | 33479 | 0.250 |
Why?
| | Enuresis | 1 | 2005 | 3 | 0.250 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2005 | 12 | 0.240 |
Why?
| | Renal Agents | 1 | 2005 | 5 | 0.240 |
Why?
| | Treatment Outcome | 7 | 2021 | 10811 | 0.240 |
Why?
| | Adult | 9 | 2022 | 37929 | 0.210 |
Why?
| | Hormone Replacement Therapy | 2 | 2023 | 100 | 0.210 |
Why?
| | Fibromyalgia | 1 | 2023 | 52 | 0.200 |
Why?
| | Vaping | 1 | 2024 | 60 | 0.200 |
Why?
| | Age Factors | 2 | 2022 | 3295 | 0.190 |
Why?
| | Electronics | 1 | 2023 | 76 | 0.190 |
Why?
| | Naltrexone | 1 | 2023 | 97 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2057 | 0.190 |
Why?
| | Occult Blood | 1 | 2022 | 34 | 0.190 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 740 | 0.180 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1291 | 0.180 |
Why?
| | Lipid Regulating Agents | 1 | 2020 | 2 | 0.180 |
Why?
| | Postmenopause | 1 | 2023 | 366 | 0.180 |
Why?
| | United States | 5 | 2022 | 14841 | 0.170 |
Why?
| | Fish Oils | 1 | 2020 | 26 | 0.170 |
Why?
| | Life Style | 1 | 2023 | 490 | 0.170 |
Why?
| | Time Factors | 2 | 2023 | 6828 | 0.170 |
Why?
| | Hypertriglyceridemia | 1 | 2020 | 39 | 0.170 |
Why?
| | Labor Stage, Second | 1 | 2020 | 3 | 0.170 |
Why?
| | Prenatal Care | 1 | 2022 | 294 | 0.160 |
Why?
| | Inpatients | 1 | 2024 | 500 | 0.160 |
Why?
| | Carcinoma, Basal Cell | 1 | 2020 | 75 | 0.160 |
Why?
| | Colonoscopy | 1 | 2022 | 245 | 0.160 |
Why?
| | Delivery, Obstetric | 1 | 2020 | 144 | 0.150 |
Why?
| | Pain Management | 2 | 2023 | 352 | 0.150 |
Why?
| | Ticlopidine | 1 | 2019 | 52 | 0.150 |
Why?
| | Systems Integration | 1 | 2018 | 37 | 0.150 |
Why?
| | Rho(D) Immune Globulin | 1 | 2018 | 3 | 0.150 |
Why?
| | Chondroitin Sulfates | 1 | 2018 | 32 | 0.150 |
Why?
| | Primary Prevention | 1 | 2020 | 196 | 0.150 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2018 | 13 | 0.140 |
Why?
| | Primary Health Care | 2 | 2019 | 1738 | 0.140 |
Why?
| | Netherlands | 1 | 2018 | 88 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2019 | 73 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 109 | 0.140 |
Why?
| | Citalopram | 1 | 2018 | 29 | 0.140 |
Why?
| | Arthralgia | 1 | 2018 | 56 | 0.140 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 49 | 0.140 |
Why?
| | Visual Analog Scale | 1 | 2018 | 33 | 0.140 |
Why?
| | Pneumonia, Bacterial | 1 | 2019 | 116 | 0.140 |
Why?
| | Male | 9 | 2021 | 67762 | 0.140 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 45 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 383 | 0.140 |
Why?
| | Yoga | 1 | 2018 | 31 | 0.140 |
Why?
| | Patients | 1 | 2019 | 175 | 0.140 |
Why?
| | Prurigo | 1 | 2016 | 2 | 0.130 |
Why?
| | Estrogen Replacement Therapy | 1 | 2018 | 146 | 0.130 |
Why?
| | Community-Acquired Infections | 1 | 2019 | 174 | 0.130 |
Why?
| | Pain | 2 | 2023 | 756 | 0.130 |
Why?
| | Blood Glucose | 2 | 2024 | 2186 | 0.130 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.130 |
Why?
| | Sulfonylurea Compounds | 1 | 2017 | 48 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2017 | 63 | 0.130 |
Why?
| | Gastroesophageal Reflux | 1 | 2019 | 234 | 0.130 |
Why?
| | Recurrence | 1 | 2020 | 1060 | 0.130 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 47 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2020 | 561 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 445 | 0.130 |
Why?
| | Smoking | 1 | 2024 | 1627 | 0.120 |
Why?
| | Exanthema | 1 | 2016 | 78 | 0.120 |
Why?
| | Sleep | 1 | 2022 | 755 | 0.120 |
Why?
| | Psychiatry | 1 | 2018 | 180 | 0.120 |
Why?
| | Prednisone | 1 | 2016 | 240 | 0.120 |
Why?
| | Administration, Oral | 1 | 2018 | 816 | 0.120 |
Why?
| | Injections | 1 | 2016 | 183 | 0.120 |
Why?
| | Hemorrhage | 1 | 2020 | 722 | 0.120 |
Why?
| | Diabetic Foot | 1 | 2015 | 24 | 0.120 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2019 | 463 | 0.120 |
Why?
| | Achilles Tendon | 1 | 2015 | 32 | 0.110 |
Why?
| | Acute Disease | 1 | 2018 | 1007 | 0.110 |
Why?
| | Burnout, Professional | 2 | 2019 | 442 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 792 | 0.110 |
Why?
| | Adolescent | 2 | 2025 | 21513 | 0.110 |
Why?
| | Tendon Injuries | 1 | 2015 | 68 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2019 | 642 | 0.110 |
Why?
| | Hospitalization | 1 | 2024 | 2199 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.110 |
Why?
| | Sulfonamides | 1 | 2018 | 513 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 356 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1066 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2018 | 1993 | 0.100 |
Why?
| | Gestational Age | 1 | 2017 | 910 | 0.100 |
Why?
| | Young Adult | 2 | 2023 | 13209 | 0.100 |
Why?
| | Osteomyelitis | 1 | 2015 | 132 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2015 | 688 | 0.100 |
Why?
| | Psychometrics | 1 | 2017 | 720 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 316 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 855 | 0.100 |
Why?
| | Child | 3 | 2025 | 21935 | 0.090 |
Why?
| | Alphapapillomavirus | 1 | 2010 | 39 | 0.090 |
Why?
| | Colorado | 2 | 2019 | 4565 | 0.080 |
Why?
| | Child, Preschool | 1 | 2025 | 11074 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1077 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2069 | 0.070 |
Why?
| | Prospective Studies | 1 | 2018 | 7604 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5778 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2006 | 332 | 0.050 |
Why?
| | Amitriptyline | 1 | 2023 | 21 | 0.050 |
Why?
| | Trigger Points | 1 | 2023 | 13 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3566 | 0.050 |
Why?
| | Blood Pressure | 2 | 2022 | 1786 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1483 | 0.050 |
Why?
| | Dermoscopy | 1 | 2020 | 10 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1050 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 494 | 0.040 |
Why?
| | Models, Organizational | 1 | 2019 | 151 | 0.040 |
Why?
| | Long-Term Care | 1 | 2019 | 107 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 191 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1325 | 0.030 |
Why?
| | Skin | 1 | 2020 | 752 | 0.030 |
Why?
| | Blood Sedimentation | 1 | 2015 | 39 | 0.030 |
Why?
| | Rupture | 1 | 2015 | 92 | 0.030 |
Why?
| | Foot | 1 | 2015 | 96 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 591 | 0.030 |
Why?
| | Mental Health Services | 1 | 2018 | 421 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1622 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 822 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2734 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4030 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1946 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1178 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.020 |
Why?
| | Infant | 1 | 2022 | 9465 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 10388 | 0.010 |
Why?
|
|
Lyon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|